ATAI Life Sciences

Yahoo Finance • 20 days ago

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningful and durable antidepressant effects, w... Full story

Yahoo Finance • 23 days ago

H.C. Wainwright Affirms ‘Buy’ Rating on Atai Life Sciences N.V. (ATAI) on Psychedelic Prospects

Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the best healthcare penny stocks to buy now. On September 15, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $15 price target. The positive stance follows a meeting between the... Full story

Yahoo Finance • 25 days ago

atai Life Sciences Awarded Grant from the National Institutes of Health

NEW YORK and AMSTERDAM, Sept. 18, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform... Full story

Yahoo Finance • last month

atai Life Sciences to Participate in September Investor Conferences

NEW YORK and AMSTERDAM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform... Full story

Yahoo Finance • 2 months ago

Cathie Wood Loads Up Millions on Google, AMD in Bold ARK Shift

July 29 - Cathie Wood's ARK ETFs tweaked their portfolios Monday, rotating into tech and biotech names as they fine?tune sector exposure. The biggest addition came in ARKW, where ARK bought 181,640 shares of Alphabet (NASDAQ:GOOG) for rou... Full story

Yahoo Finance • 3 months ago

Cathie Wood's ARK buys AMD and Alphabet stock, sells Coinbase and Robinhood

Cathie Wood’s ARK ETFs have made significant moves in the stock market on Monday, July 28, 2025, with a series of buys and sells that investors are keenly observing. The trades indicate a strategic adjustment of the funds’ holdings, with a... Full story

Yahoo Finance • 3 months ago

AMD and ServiceNow Highlight Monday's Market Cap Stock Movers

Monday’s market has seen notable movements among a range of stocks, with significant activity in both the mega-cap and large-cap categories. While stocks such as Adv Micro Device (NASDAQ:AMD) and ServiceNow Inc (NYSE:NOW) have experience... Full story

Yahoo Finance • 3 months ago

What's going on in today's pre-market session

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT HTOOW [https://www.chartm... Full story

Yahoo Finance • 3 months ago

Atai Life Sciences down 12% after hours on mid-stage failure of schizophrenia asset

[Crumpled piece of paper with word Schizophrenia on torn white paper pieces background.] * Atai Life Sciences (NASDAQ:ATAI [https://seekingalpha.com/symbol/ATAI]) is off ~12% in after-hours trading Friday after a company it has a signif... Full story

Yahoo Finance • 3 months ago

Top movers in Friday's after hours session

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] GAINERS TICKER CHANGE COMMENT MCVT [https://www.chartmill.com/stock/quote/MCVT/profile] 14.75%... Full story

Yahoo Finance • 3 months ago

Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating

Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the 13 Best German Stocks to Invest in Now. On July 2, analysts at Canaccord Genuity lifted the stock’s price target from $11 to $12, while maintaining a Buy rating for its shares.Canaccord G... Full story

Yahoo Finance • 3 months ago

atai Life Sciences stock rating reiterated at Buy by Aegis Capital

Investing.com - Aegis Capital has reiterated its Buy rating and $8.00 price target on atai Life Sciences N.V (NASDAQ:ATAI) following positive Phase 2b results for the company’s BPL-003 treatment for Treatment Resistant Depression (TRD). Th... Full story

Yahoo Finance • 3 months ago

atai Life Sciences stock price target raised to $12 by Canaccord on positive trial data

Investing.com - Canaccord Genuity has raised its price target on atai Life Sciences N.V (NASDAQ:ATAI) to $12.00 from $11.00 while maintaining a Buy rating following positive Phase 2b clinical trial results. Currently trading at $2.71, the... Full story

Yahoo Finance • 3 months ago

Cathie Wood's ARK ETF adjusts portfolio, buys Tesla and ATAI stock

Cathie Wood’s ARK ETFs have made their latest round of daily trades on Tuesday, 01 July 2025, with significant activity across a variety of sectors. In a notable move, ARK has increased its holdings in Tesla Inc (NASDAQ:TSLA) with a substa... Full story

Yahoo Finance • 3 months ago

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

PALM BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Worldwide, there is a rising demand for neuropsychiatric disorder treatments which is expected to fuel the global markets for years to come. With expand... Full story

Yahoo Finance • 3 months ago

Atai rises as psychedelic drug succeeds in mid-stage trial for depression

[Mental disorder, deep learning concept] Eoneren/E+ via Getty Images Shares of atai Life Sciences (NASDAQ:ATAI [https://seekingalpha.com/symbol/ATAI]) traded higher in the premarket on Tuesday after the company and its partner, Beckley Ps... Full story

Yahoo Finance • 3 months ago

atai Life Sciences raises $50M in private financing

* atai Life Sciences (NASDAQ:ATAI [https://seekingalpha.com/symbol/ATAI]) has announced a $50M private placement financing. * The company entered into subscription agreements related to the purchase of 18,264,840 ordinary shares and pr... Full story

Yahoo Finance • 3 months ago

atai Life Sciences secures $50 million in private placement funding

NEW YORK/AMSTERDAM - Clinical-stage biopharmaceutical company atai Life Sciences (NASDAQ:ATAI), which has seen its stock surge over 64% in the past six months according to InvestingPro data, announced Tuesday it has entered into agreements... Full story

Yahoo Finance • 3 months ago

atai Life Sciences Announces $50 Million Private Placement Financing

NEW YORK and AMSTERDAM, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outco... Full story

Yahoo Finance • 3 months ago

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single dose Both 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically... Full story